Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Despite Lars Fruergaard Jørgensen's resignation as Novo Nordisk's CEO, its stock price has risen 10% over the past two weeks.

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than ...

Hansal Mehta's weight loss journey using Mounjaro sparked debate in India. AIIMS endocrinologist Dr. Yashdeep Gupta ...

The new move comes as Eli Lilly has also taken action against compounders making copies of tirzepatide, its GLP-1 and GIP agonist sold as Mounjaro for diabetes and Zepbound for obesity in the US.

Meanwhile, a team at Brigham and Women's Hospital in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing on ...